- Monoclonal Antibody
- Steroids
- Artificial Tear Drops
- Other Treatment Types
Thyroid Eye Disease Treatment Market was valued at USD 2,375.2 million in 2023 and is expected to grow at a 7.8% CAGR from 2024 to 2030. Thyroid Eye Disease (TED), also known as Graves' ophthalmopathy, is an autoimmune inflammatory disorder that affects the orbital tissues, causing a range of ocular symptoms from mild to severe. The thyroid eye disease treatment market's expansion is primarily fueled by the rising incidence of thyroid disorders worldwide, particularly Graves' disease, which is closely associated with thyroid eye disease. A major driver has been the introduction of novel biologic therapies, which have revolutionized treatment approaches for moderate to severe thyroid eye disease cases, offering more targeted and effective options than traditional treatments. This innovation has not only improved patient outcomes but also attracted substantial investment in research and development from pharmaceutical companies. The growing awareness among healthcare providers and patients about the long-term impacts of untreated thyroid eye disease on quality of life has further stimulated demand for advanced treatments. However, the market faces challenges, including the high cost of newer treatments, particularly biologics, which can limit access for many patients, especially in regions with inadequate healthcare coverage.
Reimbursement issues and varying insurance policies across different countries also pose obstacles to treatment adoption. Additionally, potential side effects associated with long-term use of certain medications necessitate careful patient monitoring and may restrict treatment duration. Despite these challenges, the market presents significant opportunities, particularly in emerging economies where improving healthcare infrastructure and rising awareness about thyroid eye disease are expanding the patient pool. The trend towards personalized medicine opens avenues for developing more targeted therapies based on individual patient profiles, potentially enhancing treatment efficacy and minimizing side effects. Telemedicine's rapid expansion, accelerated by the COVID-19 pandemic, offers opportunities to improve access to specialized care, especially for patients in remote areas. Current trends in the market include a focus on combination therapies, integrating different treatment approaches to optimize outcomes, and increasing collaborations between pharmaceutical companies and research institutions to accelerate the development of novel treatment modalities. The growing emphasis on patient-centric care models and the integration of artificial intelligence in diagnostic and treatment planning processes are also shaping the market's evolution, promising more efficient and personalized management of thyroid eye disease in the future.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The dynamics of the Thyroid Eye Disease Treatment market are shaped by a complex interplay of factors. A primary driver is the increasing prevalence of thyroid disorders globally, particularly Graves' disease, which is the most common cause of hyperthyroidism and is closely associated with thyroid eye disease. The growing awareness among healthcare providers about the importance of early diagnosis and treatment of thyroid eye disease has led to increased referrals to specialists and earlier interventions, positively impacting market growth. Advancements in diagnostic technologies, including high-resolution imaging techniques and biomarker testing, have improved the accuracy and speed of thyroid eye disease diagnosis, facilitating timely treatment initiation. The introduction of targeted biologic therapies has been a game-changer in the market, offering more effective treatment options for patients with moderate to severe thyroid eye disease and potentially reducing the need for invasive surgical interventions. These innovative treatments have not only improved patient outcomes but have also attracted significant investment in research and development from pharmaceutical companies, further driving market expansion.
The Thyroid Eye Disease Treatment Market was valued at USD 2,375.2 million in 2023 and is expected to grow at a 7.8% CAGR from 2024 to 2030.
Pfizer Inc., Novartis AG, Johnson & Johnson Services, Inc., AbbVie Inc., and Cipla Inc. are some of the major players operating in the Thyroid Eye Disease Treatment market.
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the Thyroid Eye Disease Treatment market.
Factors like the high cost of newer treatments, particularly biologics, which can limit access for many patients, especially in regions with inadequate healthcare coverage are expected to limit the growth of the Thyroid Eye Disease Treatment market.
1.Executive Summary |
2.Global Thyroid Eye Disease Treatment Market Introduction |
2.1.Global Thyroid Eye Disease Treatment Market - Taxonomy |
2.2.Global Thyroid Eye Disease Treatment Market - Definitions |
2.2.1.Treatment Type |
2.2.2.Distribution Channel |
2.2.3.Region |
3.Global Thyroid Eye Disease Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Thyroid Eye Disease Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Thyroid Eye Disease Treatment Market By Treatment Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Monoclonal Antibody |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Steroids |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Artificial Tear Drops |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Other Treatment Types |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Thyroid Eye Disease Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Hospital Pharmacy |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Retail Pharmacy |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Ambulatory Surgical Centers |
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. E-commerce |
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Thyroid Eye Disease Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. North America |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Europe |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Asia Pacific (APAC) |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Middle East and Africa (MEA) |
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Latin America |
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
8.North America Thyroid Eye Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Treatment Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.1.1.Monoclonal Antibody |
8.1.2.Steroids |
8.1.3.Artificial Tear Drops |
8.1.4.Other Treatment Types |
8.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.2.1.Hospital Pharmacy |
8.2.2.Retail Pharmacy |
8.2.3.Ambulatory Surgical Centers |
8.2.4.E-commerce |
8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
8.3.1.United States of America (USA) |
8.3.2.Canada |
9.Europe Thyroid Eye Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Monoclonal Antibody |
9.1.2.Steroids |
9.1.3.Artificial Tear Drops |
9.1.4.Other Treatment Types |
9.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Hospital Pharmacy |
9.2.2.Retail Pharmacy |
9.2.3.Ambulatory Surgical Centers |
9.2.4.E-commerce |
9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Germany |
9.3.2.France |
9.3.3.Italy |
9.3.4.United Kingdom (UK) |
9.3.5.Spain |
10.Asia Pacific (APAC) Thyroid Eye Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Monoclonal Antibody |
10.1.2.Steroids |
10.1.3.Artificial Tear Drops |
10.1.4.Other Treatment Types |
10.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Hospital Pharmacy |
10.2.2.Retail Pharmacy |
10.2.3.Ambulatory Surgical Centers |
10.2.4.E-commerce |
10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.China |
10.3.2.India |
10.3.3.Australia and New Zealand (ANZ) |
10.3.4.Japan |
10.3.5.Rest of APAC |
11.Middle East and Africa (MEA) Thyroid Eye Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Monoclonal Antibody |
11.1.2.Steroids |
11.1.3.Artificial Tear Drops |
11.1.4.Other Treatment Types |
11.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Hospital Pharmacy |
11.2.2.Retail Pharmacy |
11.2.3.Ambulatory Surgical Centers |
11.2.4.E-commerce |
11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.GCC Countries |
11.3.2.South Africa |
11.3.3.Rest of MEA |
12.Latin America Thyroid Eye Disease Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Monoclonal Antibody |
12.1.2.Steroids |
12.1.3.Artificial Tear Drops |
12.1.4.Other Treatment Types |
12.2. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Hospital Pharmacy |
12.2.2.Retail Pharmacy |
12.2.3.Ambulatory Surgical Centers |
12.2.4.E-commerce |
12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Brazil |
12.3.2.Mexico |
12.3.3.Rest of LA |
13. Competition Landscape |
13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
13.2.1.Horizon Therapeutics PLC |
13.2.2.Pfizer Inc. |
13.2.3.Novartis AG |
13.2.4.Johnson & Johnson Services, Inc. (Johnson & Johnson Vision Care, Inc.) |
13.2.5.AbbVie Inc. |
13.2.6.Cipla Inc. |
13.2.7.Bausch & Lomb Incorporated |
13.2.8.Sun Pharmaceutical Industries, Inc. |
13.2.9.Eyevance Pharmaceuticals LLC |
13.2.10.Alcon Inc. |
14. Research Methodology |
15. Appendix and Abbreviations |